Novel Drug Delivery Systems Market, By Route of Administration (Oral Drug Delivery Systems, Injectable Drug Delivery Systems, Pulmonary Drug Delivery Systems, Transdermal Drug Delivery Systems, and Other Routes of Administration), By Mode of NDDS (Targeted Drug Delivery Systems, Controlled Drug Delivery Systems, and Modulated Drug Delivery Systems), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030

The novel drug delivery system is the controlled release of the drugs which is selective targeting of drugs to the site of action. Novel drug delivery system is the try to make ideal drugs. NDDS transport the drugs intact to the site of action avoiding the non-diseased tissue. NDDS is stable and delivery can be maintained under the various physiological variables. Drug delivery refers to approaches, formulations, manufacturing techniques, storage systems, and technologies involved in transporting a pharmaceutical compound to its target site to realize a desired therapeutic effect. Principles associated with drug preparation, route of administration, site-specific targeting, metabolism, and toxicity are wont to optimize efficacy and safety, and to enhance patient convenience and compliance. Drug delivery is aimed toward altering a drug's pharmacokinetics and specificity by formulating it with different excipients, drug carriers, and medical devices. There’s additional emphasis on increasing the bioavailability and duration of action of a drug to enhance therapeutic outcomes. Some research has also been focused on improving safety for the person administering the medication. For instance , several sorts of microneedle patches are developed for administering vaccines and other medications to scale back the danger of needlestick injury. The Global Novel Drug Delivery Systems Market accounted for US$ 23.05 billion in 2020 and is estimated to be US$ 29.39 billion by 2030 and is anticipated to register a CAGR of 2.50%.

Requirement of controlled release of drugs

The requirement of controlled release of drugs because most of the drugs have an optimum range of concentration in the body which is the major driving factor for the growth of the global market. Additionally, technological advancements promoting the development of novel drugs delivery systems which is another propelling factor for the growth of the target market. For instance, in October 2017, the team of researchers at the IISC (Indian Institute of Science), India, designed a novel chemical compound which can be tailored to release aspirin inside the body, during the desired duration.

Strict government regulatory guidelines

However, stringent the government regulatory guidelines associate with developing novel drug delivery systems which is the major restraining factor for the growth of the target market. Nevertheless, the advancement in the drug delivery systems and increasing investment in the R&D for development of NDDS can create an opportunity for the global market.

The global novel drug delivery systems market is segmented based on the product, mechanism, route of administration, mode of NDDS, and region.

Based on the route of administration, the global market is classified into oral drug delivery systems, injectable drug delivery systems, pulmonary drug delivery systems, transdermal drug delivery systems, and other routes of administration. Based on the mode of NDDS, the target market is bifurcated into targeted drug delivery systems, controlled drug delivery systems, and modulated drug delivery systems.

Regional Insights:

Based on the region the global novel drug delivery systems market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America accounts highest revenue share to the global novel drug delivery systems market due to increasing inclination towards the self- administration of drugs and rise in innovation in injectable drug delivery systems.

Detailed Segmentation:

Global Novel Drug Delivery Systems Market, By Region:

• • • North America
      • North America Novel Drug Delivery Systems Market, By Route of Administration
      • North America Novel Drug Delivery Systems Market, By Mode of NDDS
      • North America Novel Drug Delivery Systems Market, By Country
        • The U.S.
        • Canada
    • Europe
      • Europe Novel Drug Delivery Systems Market, By Route of Administration
      • Europe Novel Drug Delivery Systems Market, By Mode of NDDS
      • Europe Novel Drug Delivery Systems Market, By Country
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Asia Pacific Novel Drug Delivery Systems Market, By Route of Administration
      • Asia Pacific Novel Drug Delivery Systems Market, By Mode of NDDS
      • Asia Pacific Novel Drug Delivery Systems Market, By Country
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Latin America Novel Drug Delivery Systems Market, By Route of Administration
      • Latin America Novel Drug Delivery Systems Market, By Mode of NDDS
      • Latin America Novel Drug Delivery Systems Market, By Country
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Middle East & Africa Novel Drug Delivery Systems Market, By Route of Administration
      • Middle East & Africa Novel Drug Delivery Systems Market, By Mode of NDDS
      • Middle East & Africa Novel Drug Delivery Systems Market, By Country
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating the global novel drug delivery systems market involves Abbott Laboratories, AstraZeneca PLC, Bayer AG, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, and Sanofi SA. Prominent players operating in the target market are focusing on strategic partnerships as well as the launching of the products to gain a competitive edge in the target market. For instance, Abbott acquired Alere Inc. (Alere), a diagnostic device and service provider to strengthen the company's presence in the diagnostics markets.

• • • Abbott Laboratories
      • • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Business Strategy
    • AstraZeneca PLC
      • • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Business Strategy
    • Bayer AG
      • • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Business Strategy
    • GlaxoSmithKline PLC
      • • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Business Strategy
    • Johnson & Johnson
      • • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Business Strategy
    • Merck & Co. Inc.
      • • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Business Strategy
    • Novartis AG
      • • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Business Strategy
    • Pfizer Inc.
      • • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Business Strategy
    • Roche Holding AG
      • • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Business Strategy
    • Sanofi SA
      • • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Business Strategy